MARKET

SRNE

SRNE

Sorrento Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.08
+0.14
+1.76%
Closed 19:49 09/16 EDT
OPEN
7.93
PREV CLOSE
7.94
HIGH
8.08
LOW
7.93
VOLUME
2.56M
TURNOVER
--
52 WEEK HIGH
17.25
52 WEEK LOW
5.17
MARKET CAP
2.41B
P/E (TTM)
-6.9225
1D
5D
1M
3M
1Y
5Y
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients - Financial News Media
Palm Beach, FL - September 14, 2021 – FinancialNewsMedia.com News Commentary – All across the globe, innumerable scientists are looking to beat COVID-19... the two main paths are to find better vaccines and to utilize better treatments. As with most viruse...
MENAFN · 2d ago
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients
/PRNewswire/ --  - All across the globe, innumerable scientists are looking to beat COVID-19… the two main paths are to find better vaccines and to utilize better treatments. As with most viruses, developing COVID-19 treatments has been difficult, but seve...
PR Newswire - PRF · 2d ago
Dr. Henry Ji, Sorrento Chairman and CEO, to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the H.C. Wainwright 23rd Global Investment Conference (www.hcwevents.com/annualco...
GlobeNewswire · 3d ago
The Vaccine Revolution Portfolio (MRNA, PFE, JNJ, NVAX, BNTX, AZN, DYAI)
WallStreetPR · 09/08 13:10
New Strong Sell Stocks for September 8th
Zacks.com · 09/08 13:09
Celsion (CLSN) COVID Vaccine Effective in Pre-Clinical Studies
Zacks.com · 09/03 16:40
Sorrento Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients
First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.   Second site scheduled to start enrolling within one week, with multiple additional sites coming online within
Benzinga · 09/02 15:35
BRIEF-Sorrento Announces Enrollment Of First Subject In Brazil Phase 2 Study Of Covi-Msc
reuters.com · 09/02 15:35
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SRNE. Analyze the recent business situations of Sorrento Thera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SRNE stock price target is 26.67 with a high estimate of 35.00 and a low estimate of 19.00.
EPS
Institutional Holdings
Institutions: 272
Institutional Holdings: 83.39M
% Owned: 27.97%
Shares Outstanding: 298.10M
TypeInstitutionsShares
Increased
69
6.49M
New
30
1.24M
Decreased
52
5.46M
Sold Out
46
2.16M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.83%
Pharmaceuticals & Medical Research
+0.11%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Director
Henry Ji
Chief Financial Officer/Senior Vice President
Najjam Asghar
Lead Director/Independent Director
Dorman Followwill
Director
Kim Janda
Director
Jaisim Shah
Independent Director
David Lemus
Independent Director
Robin Smith
Independent Director
Yue Wu
No Data
About SRNE
Sorrento Therapeutics, Inc. is a clinical-stage, antibody-centric, biopharmaceutical company developing therapies to treat cancers and COVID-19. The Company's segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its proprietary G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. The Company's multimodal, multipronged approach to fighting cancer is made possible by immuno-oncology platforms, including key assets such as fully human antibodies, clinical-stage immuno-cellular therapies, antibody-drug conjugates, and clinical-stage oncolytic virus. It is also developing potential antiviral therapies and vaccines against coronaviruses, which includes COVI-GUARD, COVI-AMG, COVI-SHIELD, Gene-MAb, COVI-MSC, and COVI-DROPS.

Webull offers kinds of Sorrento Therapeutics Inc stock information, including NASDAQ:SRNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRNE stock methods without spending real money on the virtual paper trading platform.